‘How Long Do I Have?’ – Examining survival outcomes in laryngeal cancer patients managed with non-curative intent in Northern UK: Insights from the Northern Head & Neck Cancer Alliance Retrospective Study

IF 1.7 4区医学 Q2 OTORHINOLARYNGOLOGY

Clinical Otolaryngology Pub Date : 2024-12-11 DOI:10.1111/coa.14260

Amarkumar Rajgor, Rhona Hurley, Catriona M. Douglas, Claire Paterson, James Moor, Shane Lester, Sara Sionis, Katharine Davies, James O'Hara, Gareth Inman, Terry Jones, David Winston Hamilton, Northern Head & Neck Alliance

{"title":"‘How Long Do I Have?’ – Examining survival outcomes in laryngeal cancer patients managed with non-curative intent in Northern UK: Insights from the Northern Head & Neck Cancer Alliance Retrospective Study","authors":"Amarkumar Rajgor, Rhona Hurley, Catriona M. Douglas, Claire Paterson, James Moor, Shane Lester, Sara Sionis, Katharine Davies, James O'Hara, Gareth Inman, Terry Jones, David Winston Hamilton, Northern Head & Neck Alliance","doi":"10.1111/coa.14260","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Historically, 15% of laryngeal cancer patients undergo non-curative management, but pragmatic data on this group are limited. This information is crucial to help patients make informed decisions about their care. Supported by the Northern Head & Neck Alliance, this retrospective study is the first to present survival outcomes for non-curative laryngeal cancer patients in Northern UK.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Retrospective data were compiled for patients with laryngeal squamous cell cancer from five large tertiary head and neck centres in Northern UK (Newcastle, Glasgow, Sheffield, Leeds, and Middlesbrough). The collected data encompassed demographic details, treatment and clinical outcomes.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 373 patients, the mean age was 72, and 73% were male. The median follow-up was 6 months. 17% had early-stage (T1-2), and 83% had late-stage (T3-4) disease. By data collection, 99% had died.</p>\n \n <p>The mean survival time (MST) was 9.1 months. Patients with metastases had an MST of 6.9 months, while those without had 9.4 months. Early-stage patients had an MST of 13.3 months, compared to 8.2 months for advanced disease. By subsite, MSTs were 8.2 months for supraglottic, 12.5 for glottic, 5.5 for subglottic, and 7.9 for transglottic cancers.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study stands as the first to explore survival outcomes in laryngeal cancer patients undergoing non-curative management. The findings can provide valuable insights for informing patients about survival in the absence of radical treatment, facilitating important decision-making conversations.</p>\n </section>\n </div>","PeriodicalId":10431,"journal":{"name":"Clinical Otolaryngology","volume":"50 2","pages":"344-351"},"PeriodicalIF":1.7000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/coa.14260","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Otolaryngology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/coa.14260","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Historically, 15% of laryngeal cancer patients undergo non-curative management, but pragmatic data on this group are limited. This information is crucial to help patients make informed decisions about their care. Supported by the Northern Head & Neck Alliance, this retrospective study is the first to present survival outcomes for non-curative laryngeal cancer patients in Northern UK.

Methods

Retrospective data were compiled for patients with laryngeal squamous cell cancer from five large tertiary head and neck centres in Northern UK (Newcastle, Glasgow, Sheffield, Leeds, and Middlesbrough). The collected data encompassed demographic details, treatment and clinical outcomes.

Results

Among 373 patients, the mean age was 72, and 73% were male. The median follow-up was 6 months. 17% had early-stage (T1-2), and 83% had late-stage (T3-4) disease. By data collection, 99% had died.

The mean survival time (MST) was 9.1 months. Patients with metastases had an MST of 6.9 months, while those without had 9.4 months. Early-stage patients had an MST of 13.3 months, compared to 8.2 months for advanced disease. By subsite, MSTs were 8.2 months for supraglottic, 12.5 for glottic, 5.5 for subglottic, and 7.9 for transglottic cancers.

Conclusion

This study stands as the first to explore survival outcomes in laryngeal cancer patients undergoing non-curative management. The findings can provide valuable insights for informing patients about survival in the absence of radical treatment, facilitating important decision-making conversations.

Abstract Image

查看原文本刊更多论文

“我还有多长时间？”-检查英国北部非治愈目的喉癌患者的生存结果：来自北方头颈癌联盟回顾性研究的见解。

简介：历史上，15%的喉癌患者接受非治愈性治疗，但这一群体的实际数据有限。这些信息对于帮助患者做出明智的护理决定至关重要。在北方头颈联盟的支持下，这项回顾性研究首次展示了英国北部无法治愈的喉癌患者的生存结果。方法：回顾性收集来自英国北部五个大型三级头颈中心（纽卡斯尔、格拉斯哥、谢菲尔德、利兹和米德尔斯堡）的喉部鳞状细胞癌患者的资料。收集的数据包括人口统计细节、治疗和临床结果。结果：373例患者中，平均年龄72岁，男性占73%。中位随访时间为6个月。17%为早期（T1-2）， 83%为晚期（T3-4）。根据数据收集，99%的人已经死亡。平均生存时间（MST）为9.1个月。转移患者的MST为6.9个月，而无转移患者的MST为9.4个月。早期患者的MST为13.3个月，而晚期患者为8.2个月。按亚位点划分，声门上癌的mst为8.2个月，声门下癌为12.5个月，声门外癌为5.5个月，声门外癌为7.9个月。结论：本研究首次探讨了接受非治愈治疗的喉癌患者的生存结果。这些发现可以提供有价值的见解，告知患者在没有根治性治疗的情况下的生存情况，促进重要的决策对话。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Otolaryngology 医学-耳鼻喉科学

CiteScore

4.00

自引率

4.80%

发文量

106

审稿时长

>12 weeks

期刊介绍： Clinical Otolaryngology is a bimonthly journal devoted to clinically-oriented research papers of the highest scientific standards dealing with: current otorhinolaryngological practice audiology, otology, balance, rhinology, larynx, voice and paediatric ORL head and neck oncology head and neck plastic and reconstructive surgery continuing medical education and ORL training The emphasis is on high quality new work in the clinical field and on fresh, original research. Each issue begins with an editorial expressing the personal opinions of an individual with a particular knowledge of a chosen subject. The main body of each issue is then devoted to original papers carrying important results for those working in the field. In addition, topical review articles are published discussing a particular subject in depth, including not only the opinions of the author but also any controversies surrounding the subject. • Negative/null results In order for research to advance, negative results, which often make a valuable contribution to the field, should be published. However, articles containing negative or null results are frequently not considered for publication or rejected by journals. We welcome papers of this kind, where appropriate and valid power calculations are included that give confidence that a negative result can be relied upon.